Chris Verslype

28.5k citations
343 papers · 16.3k · 6 hit papers · h-index 52

Impact in

  • Hepatology top 0.05%
    • Hepatocellular Carcinoma Treatment and Prognosis
    • Liver Disease and Transplantation
    • Liver physiology and pathology
  • Oncology top 0.1%
    • Colorectal Cancer Treatments and Studies
    • Pancreatic and Hepatic Oncology Research

Papers in

    • Hepatocellular Carcinoma Treatment and Prognosis 65
    • Liver Disease and Transplantation 33
    • Pancreatic and Hepatic Oncology Research 31
    • Lung Cancer Research Studies 30
    • Colorectal Cancer Treatments and Studies 27

Chris Verslype

329 papers receiving 15.7k citations

Chris Verslype's Hit Papers

Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines 2021 · 314 citations
3140+7+14Years since publication10002.0k3.0k4.0k

Peers

Chris Verslype
Comparison fields: 5 of 154
  • Hepatology 5.4k
  • Oncology 6.2k
  • Cancer Research 1.7k
  • Pulmonary and Respiratory Medicine 2.8k
  • Epidemiology 2.8k
Replace Alan P. Venook with:
Alan P. Venook United States
Sheung Tat Fan Hong Kong
Arndt Vogel Germany
Joel K. Greenson United States
Takuji Okusaka Japan
Bruno Sangro Spain
Alexis Laurent France
David M. Nagorney United States
Norihiro Kokudo Japan
Robin Kate Kelley United States
Chris Verslype relative to Alan P. Venook United States Alan P. Venook's profile →
Citations per field
00.5×1.5×
Alan P. Venook · 1×
Citations per year

Countries citing papers authored by Chris Verslype

Since Specialization
Citations

This map shows the geographic impact of Chris Verslype's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chris Verslype with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chris Verslype more than expected).

Fields of papers citing papers by Chris Verslype

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chris Verslype. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chris Verslype. The network helps show where Chris Verslype may publish in the future.

Co-authors

The 25 scholars most cited alongside Chris Verslype, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Chris Verslype Line = papers co-authored together Chris Verslype links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 343 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
Hit paper breakdown →
20044041
2
Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Hit paper breakdown →
2018734
3
Phase III Trial of Gemcitabine Plus Tipifarnib Compared With Gemcitabine Plus Placebo in Advanced Pancreatic Cancer
Hit paper breakdown →
2004647
4
Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer
Hit paper breakdown →
2009530
5 2003373
6 2006350
7
Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines
Hit paper breakdown →
2021314
8 2012310
9 2008299
10 2010289
11 2007268
12 2012250
13
Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma
Hit paper breakdown →
2019249
14 2006222
15 2019208
16 2006195
17 2010192
18 2007176
19 2006155
20 2012153

About Chris Verslype

Chris Verslype is a scholar working on Hepatology, Oncology, Epidemiology, Surgery and Pulmonary and Respiratory Medicine, having authored 343 papers that have together received 16.3k indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (65 papers), Neuroendocrine Tumor Research Advances (47 papers), Liver Disease Diagnosis and Treatment (38 papers), Liver Disease and Transplantation (33 papers), Pancreatic and Hepatic Oncology Research (31 papers), Lung Cancer Research Studies (30 papers), Colorectal Cancer Treatments and Studies (27 papers) and Neuroblastoma Research and Treatments (23 papers). The work is most often cited by research in Hepatology (5.4k citations), Oncology (6.2k citations), Cancer Research (1.7k citations), Pulmonary and Respiratory Medicine (2.8k citations) and Epidemiology (2.8k citations). Chris Verslype has collaborated with scholars based in Belgium, United States and Germany. Frequent co-authors include Eric Van Cutsem, Yves Humblet, Ian Chau, Frederik Nevens, David Khayat, Harry Bleiberg, David Cunningham, A. Harstrick, M. Mueser and Armando Santoro. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Journal of Hepatology, European Journal of Gastroenterology & Hepatology and Hepatology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact